ArticleInfection and immunity2001
Oral immunization with recombinant Streptococcus gordonii expressing porphyromonas gingivalis FimA domains.
Article in Infection and immunity, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Review
- Review
- Oral microbiota-host interaction: the chief culprit of alveolar bone resorption.Frontiers in immunology · 2024Review
- CpG immunostimulatory oligodeoxynucleotide 1826 as a novel nasal ODN adjuvant enhanced the protective efficacy of the periodontitis gene vaccine in a periodontitis model in SD rats.BMC oral health · 2021Article
- Mucosal Vaccination Against Periodontal Disease: Current Status and Opportunities.Frontiers in immunology · 2021Review
- Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy.Periodontology 2000 · 2020Review
- Persistence ofCurrent oral health reports · 2020Article
- Article
- Review
- Recombinant fimbriae protein of Porphyromonas gingivalis induces an inflammatory response via the TLR4/NF‑κB signaling pathway in human peripheral blood mononuclear cells.International journal of molecular medicine · 2019Article
- Lactic acid bacteria - promising vaccine vectors: possibilities, limitations, doubts.Journal of applied microbiology · 2017Review
- Gene therapy in periodontics.Journal of Indian Society of Periodontology · 2013Article
- Streptococcus cristatus ArcA interferes with Porphyromonas gingivalis pathogenicity in mice.Journal of periodontal research · 2012Article
- Novel and often bizarre strategies in the treatment of periodontal disease.Journal of Indian Society of Periodontology · 2012Article
- Vaccines against periodontitis: a forward-looking review.Journal of periodontal & implant science · 2010Article
- Production of Monoclonal Antibodies Specific to FimA of Porphyromonas gingivalis and Their Inhibitory Activity on Bacterial Binding.Immune network · 2009Article
- Synthesis and assembly of Porphyromonas gingivalis fimbrial protein in potato tissues.Molecular biotechnology · 2009Article
- Toll gates to periodontal host modulation and vaccine therapy.Periodontology 2000 · 2009Review
- The use of rodent models to investigate host-bacteria interactions related to periodontal diseases.Journal of clinical periodontology · 2008Review
- Commensal bacteria as a novel delivery system for subunit vaccines directed against agents of bioterrorism.Advanced drug delivery reviews · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Porphyromonas gingivalis, a gram-negative anaerobe, is implicated in the etiology of adult periodontitis. P. gingivalis fimbriae are one of several critical surface virulence factors involved in both bacterial adherence and inflammation. P. gingivalis fimbrillin (FimA), the major subunit protein of fimbriae, is considered an important antigen for vaccine development against P. gingivalis-associated periodontitis. We have previously shown that biologically active domains of P. gingivalis fimbrillin can be expressed on the surface of the human commensal bacterium Streptococcus gordonii. In this study, we examined the effects of oral coimmunization of germfree rats with two S. gordonii recombinants expressing N (residues 55 to 145)- and C (residues 226 to 337)-terminal epitopes of P. gingivalis FimA to elicit FimA-specific immune responses. The effectiveness of immunization in protecting against alveolar bone loss following P. gingivalis infection was also evaluated. The results of this study show that the oral delivery of P. gingivalis FimA epitopes via S. gordonii vectors resulted in the induction of FimA-specific serum (immunoglobulin G [IgG] and IgA) and salivary (IgA) antibody responses and that the immune responses were protective against subsequent P. gingivalis-induced alveolar bone loss. These results support the potential usefulness of the S. gordonii vectors expressing P. gingivalis fimbrillin as a mucosal vaccine against adult periodontitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.